What it is: A lab-engineered fusion protein designed to block myostatin and related signals that limit muscle growth by acting as a decoy receptor.
Research suggests: Phase 2 clinical trials showed significant increases in lean muscle mass, but the trials were halted due to vascular side effects.
Best for: Muscle disease and body composition researchers
Key thing to know: Human trials were stopped due to safety concerns; it is not in active development and represents a cautionary example in the field.
What is ACE-031?
ACE-031 is a fusion protein developed by Acceleron Pharma, constructed by combining the extracellular domain of activin receptor type IIA (ActRIIA) with a human IgG1 Fc region. It functions as a ligand trap, binding and neutralizing myostatin, activins, GDF-11, and other members of the TGF-beta superfamily that signal through ActRIIA to limit muscle growth.
Unlike direct myostatin antibodies, ACE-031 blocks the receptor rather than the individual ligand. This broader approach intercepts multiple growth-limiting signals simultaneously, producing more pronounced effects on muscle mass than myostatin-specific approaches in preclinical models. The same breadth that makes it potent also creates off-target effects on other TGF-beta family signaling pathways, including bone morphogenetic proteins (BMPs).
Phase 2 clinical trials were conducted in boys with Duchenne Muscular Dystrophy. The trials were halted by the sponsor after reports of telangiectasias (small dilated skin vessels), nosebleeds, and gum bleeding in participants. These adverse effects were attributed to off-target inhibition of BMP signaling in vascular tissue.
Despite the halt, the trials did demonstrate increases in lean body mass and thigh muscle volume, confirming biological activity in humans.
How it works.
ACE-031 works as a decoy receptor. By circulating in the bloodstream and binding myostatin, GDF-11, and activins before they can reach their natural cell-surface receptors, it prevents these ligands from delivering their growth-inhibiting signals to muscle cells. Myostatin in particular is a potent negative regulator of skeletal muscle mass.
Animals genetically lacking myostatin develop dramatically larger muscles, which established the original scientific interest in blocking this pathway.
With myostatin and related signals suppressed, the balance of anabolic and catabolic signaling in muscle shifts toward growth. Satellite cell activation and muscle protein synthesis are relatively unopposed. In the Duchenne clinical trials, this translated into measurable increases in lean mass and muscle volume over a relatively short treatment period.
The mechanism also affects bone formation. ActRIIA is expressed in osteoblasts, and some BMP ligands signal through it to support bone remodeling. Blocking ActRIIA with ACE-031 may increase bone density by removing inhibitory BMP signals, which explains why bone density improvements appeared in preclinical models.
The vascular telangiectasias observed clinically are thought to arise from the same mechanism acting on endothelial cells that express ActRIIA and rely on normal BMP signaling for vascular integrity.
What the research shows.
ACE-031 reached Phase 2 human trials in Duchenne Muscular Dystrophy, which provides more human data than many compounds in this library. The trials confirmed biological activity: participants showed statistically significant increases in total lean mass and thigh muscle volume compared to placebo. This is meaningful proof of concept in humans.
However, the trials were halted by the sponsor due to safety signals. The adverse effects observed, specifically telangiectasias, nosebleeds, and gum bleeding, were not life-threatening but were unexpected and attributed to off-target vascular effects of ActRIIA blockade. The sponsor discontinued the DMD program and no further human trials have been conducted with this specific compound.
The combination of confirmed human efficacy and a halted trial due to safety signals places ACE-031 in a distinct position: it is not "unproven" in the sense of lacking human data, but it also cannot be classified as having moderate or strong evidence given that its development was stopped due to vascular adverse effects. The current evidence supports studying the pathway but not the compound itself in most contexts.
Biomarkers to review first.
Research protocols examining ActRIIA pathway compounds typically reference the following baseline biomarkers. Given the vascular effects observed in clinical trials, a broader baseline evaluation is especially relevant before exploring any compound in this class.
What it's commonly researched with.
ACE-031 is not studied in combination protocols in clinical literature, given that development was halted. The compounds below appear alongside ACE-031 in the broader research context of muscle recovery, anabolic signaling, and tissue repair. These represent related areas of research, not combination recommendations.